Correlation Between PepGen and ArriVent BioPharma,

Can any of the company-specific risk be diversified away by investing in both PepGen and ArriVent BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PepGen and ArriVent BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between PepGen and ArriVent BioPharma, Common, you can compare the effects of market volatilities on PepGen and ArriVent BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PepGen with a short position of ArriVent BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of PepGen and ArriVent BioPharma,.

Diversification Opportunities for PepGen and ArriVent BioPharma,

-0.27

Correlation Coefficient

PepGen  ArriVent BioPharma,

Very good diversification

The 3 months correlation between PepGen and ArriVent is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding PepGen and ArriVent BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ArriVent BioPharma, and PepGen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PepGen are associated (or correlated) with ArriVent BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ArriVent BioPharma, has no effect on the direction of PepGen i.e., PepGen and ArriVent BioPharma, go up and down completely randomly.

Pair Corralation between PepGen and ArriVent BioPharma,

Given the investment horizon of 90 days PepGen is expected to under-perform the ArriVent BioPharma,. In addition to that, PepGen is 4.93 times more volatile than ArriVent BioPharma, Common. It trades about -0.04 of its total potential returns per unit of risk. ArriVent BioPharma, Common is currently generating about -0.18 per unit of volatility. If you would invest  2,695  in ArriVent BioPharma, Common on December 29, 2024 and sell it today you would lose (800.00) from holding ArriVent BioPharma, Common or give up 29.68% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

PepGen  vs.  ArriVent BioPharma, Common

PepGen

Risk-Adjusted Performance

Very Weak

Over the last 90 days PepGen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

ArriVent BioPharma,

Risk-Adjusted Performance

Very Weak

Over the last 90 days ArriVent BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with PepGen and ArriVent BioPharma,

The main advantage of trading using opposite PepGen and ArriVent BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PepGen position performs unexpectedly, ArriVent BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will offset losses from the drop in ArriVent BioPharma,'s long position.

The idea behind PepGen and ArriVent BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.